BioMedNewsBreaks

WednesdayMar 24, 2021 12:44 pm

BioMedNewsBreaks – 180 Life Sciences Corp. (NASDAQ: ATNF) CEO Releases Stockholder Letter

180 Life Sciences Corp. (NASDAQ: ATNF) CEO James Woody, MD, PhD, has issued a letter to ATNF stockholders. In the letter he provides an overview of the company’s activities and accomplishments since his last stockholder letter, which was released in November 2020. The letter noted the company’s achievement in both legacy-related issues and strengthening its balance sheet. A highlight mentioned in the letter was that the company had reduced its debt from $5 million to $316,000. Woody also reported that the company had converted $3 million in preferred equity to equity. In the letter, Woody also noted that the company…

Continue Reading

TuesdayMar 23, 2021 11:19 am

BioMedNewsBreaks – Vivos Therapeutics Inc. (NASDAQ: VVOS) to Present at Benzinga Biotech Conference

Vivos Therapeutics (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative treatments for patients suffering from sleep-disordered breathing, including mild-to-moderate obstructive sleep apnea (“OSA”), has announced that it will participate at the Benzinga Biotech Small Cap Conference taking place from March 24-25, 2021. Vivos Chief Executive Officer, Kirk Huntsman, Chief Financial Officer, Brad Amman, and Investor Relations Officer, Ed Loew, will be presenting at the event with their presentation scheduled to begin at 11:40 a.m. EST on Thursday, March 25, 2021. Investors interested in joining the Vivos presentation can register for a free spectator pass at https://ibn.fm/jQW0J.…

Continue Reading

TuesdayMar 23, 2021 10:59 am

BioMedNewsBreaks – Predictive Oncology (NASDAQ: POAI) Appoints Board Chair as New CEO

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announce the appointment of a new CEO: J. Melville (“Mel”) Engle. Engle is currently serving as chairman of the board and will continue to serve in that role as well as in his new position as CEO. Engle has more than two decades of impressive experience in the biotech and health-care industries. In his various roles as president, CEO, director, chairman of the board, CFO, senior vice president and more, he has gained invaluable expertise and insight into driving sales, unveiling…

Continue Reading

MondayMar 22, 2021 1:53 pm

BioMedNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Conference Call to Discuss Q4 Numbers, Clinical Pipeline Update

Processa Pharmaceuticals Inc. (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, has scheduled a conference call to discuss its fourth-quarter financial report as well as to provide a drug-development update. The conference call and life webcast will be available to any participants dialing or logging in. Interested parties can dial 877-545-0320 in the United States or 973-528-0016 for international calls; the entry code is the same for both: 805295. A replay of the call will be available as well. To access that, interested parties can…

Continue Reading

MondayMar 22, 2021 1:22 pm

BioMedNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Presents Data Regarding Drug Candidate for Replacement of Addictive Benzodiazepines

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new-generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (“CNS”) disorders, presented data highlighting the proposed mechanism of action (“MOA”) of its Phase 3 investigational drug candidate, PH94B nasal spray, in a poster session at the Anxiety and Depression Association of America’s 2021 Virtual Annual Conference. VTGN’s PH94B spray is designed to provide rapid-onset acute treatment of anxiety without directly activating gamma-amino butyric acid (“GABA-A”) receptors. This approach differentiates PH94B from benzodiazepines such as alprazolam, diazepam and lorazepam, which are…

Continue Reading

MondayMar 22, 2021 10:06 am

BioMedNewsBreaks – AzurRx BioPharma Inc. (NASDAQ: AZRX) Completes Enrollment in Phase 2 MS1819-PERT Combination Clinical Trial

AzurRx BioPharma (NASDAQ: AZRX), a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (“GI”) diseases, today announced completion of enrollment in its Phase 2 trial evaluating MS1819 in combination with the current standard of care, porcine-derived pancreatic enzyme replacement therapy (“PERT”). The combination trial is for the treatment of severe exocrine pancreatic insufficiency (“EPI”) in patients with cystic fibrosis (“CF”). “We are very pleased to have completed enrollment in our Phase 2 MS1819 plus PERT combination therapy clinical trial,” said James Sapirstein, president, CEO and chairman of AzurRx. “Based on the very encouraging clinical results…

Continue Reading

FridayMar 19, 2021 3:36 pm

BioMedNewsBreaks – RYAH Group Inc. Provides Digital Approach to Positively Impact Future Medical Treatments

RYAH Group, a leading digital health care analytics and technology company, has developed a technology that collects and analyzes patient data, creating an anonymous database that, when coupled with AI, will guide the future of medical treatments. With the technology, “patients can set usage limits, track usage in real time, record how they feel after sessions and review stats over time,” reads an article on the developments. “The patient controls the process, and the instruments that collect digital data remain anonymous. When patient feedback is optimized, medical trials and studies can move into remote solution zones… RYAH is focused on…

Continue Reading

FridayMar 19, 2021 1:19 pm

BioMedNewsBreaks – United Medical Equipment Business Solutions Network Inc.’s Test Identifies Acute COVID-19 Infection with High Sensitivity, Specificity

United Medical Equipment (“UME,” “UMEBSNI”) has made significant progress in helping the world curb the spread of COVID-19. An article on United Medical’s successes reads, “As the world attempts to control this pandemic, it is essential to quickly identify who is infected and who has already been infected. Antibody testing determines whether or not a patient has had COVID-19 in the past, while antigen testing determines whether or not a patient currently has COVID-19… Antibody tests have limited use in detection but help to determine the accurate case numbers and research into immunity.” On the other hand, antigen rapid tests…

Continue Reading

FridayMar 19, 2021 11:59 am

BioMedNewsBreaks – Bio-Path Holdings Inc. (NASDAQ: BPTH) Secures $13M in Public Offering

Bio-Path Holdings (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize(R) liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, has closed a public offering of 1,710,600 shares of common stock. Bio-Path Holdings secured approximately $13 million in gross proceeds, with each of the shares sold at the public offering price of $7.60. Bio-Path intends to use the proceeds for working capital and general corporate purposes. ROTH Capital Partners acted as sole placement agent for the offering. For more information about the company, visit www.BioPathHoldings.com About Bio-Path Holdings Inc. Bio-Path Holdings is a biotechnology…

Continue Reading

ThursdayMar 18, 2021 9:50 am

BioMedNewsBreaks – XPhyto Therapeutics Corp. (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT) Receives European Approval for 25 Minute COVID-19 PCR Test

XPhyto Therapeutics (CSE: XPHY) (OTCQB: XPHYF) (FSE: 4XT),a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities, along with its German diagnostics development partner, 3a-diagnostics GmbH ("3a"), has received European approval of its point-of-care SARS-CoV-2 RT-PCR test system, called Covid-ID Lab. Covid-ID Lab is now registered as a commercial in vitro diagnostic (CE-IVD) test in Europe, and plans are in place to launch the product in Europe in April 2021. XPhyto is exploring options with various potential distribution and wholesale partners as well as potential licensees. The test offers high sensitivity, high specificity, and high robustness,…

Continue Reading